J
James P. Snyder
Researcher at Emory University
Publications - 263
Citations - 10988
James P. Snyder is an academic researcher from Emory University. The author has contributed to research in topics: Curcumin & Receptor. The author has an hindex of 58, co-authored 263 publications receiving 10280 citations. Previous affiliations of James P. Snyder include Yerkes National Primate Research Center & G. D. Searle & Company.
Papers
More filters
Journal ArticleDOI
Subunit-specific agonist activity at NR2A-, NR2B-, NR2C-, and NR2D-containing N-methyl-D-aspartate glutamate receptors
Kevin Erreger,Matthew T. Geballe,Anders S. Kristensen,Philip E. Chen,Kasper B. Hansen,C. Justin Lee,Hongjie Yuan,Phuong Le,Polina Lyuboslavsky,Nicola Micale,Lars N. Jorgensen,Rasmus P. Clausen,David J. A. Wyllie,James P. Snyder,Stephen F. Traynelis +14 more
TL;DR: Despite high homology and conserved atomic contact residues within the agonist binding pocket of NR2A and NR2D, glutamate adopts a different binding orientation that could be exploited for the development of subunit selective agonists and competitive antagonists.
Journal ArticleDOI
Structural features of the glutamate binding site in recombinant NR1/NR2A N-methyl-D-aspartate receptors determined by site-directed mutagenesis and molecular modeling
Philip E. Chen,Matthew T. Geballe,Phillip J. Stansfeld,Alexander R. Johnston,Hongjie Yuan,Amanda L Jacob,James P. Snyder,Stephen F. Traynelis,David J. A. Wyllie +8 more
TL;DR: The modeling studies support the interpretation of the mutagenesis data and indicate a similar binding strategy for l-glutamate and NMDA when they occupy the binding site in NMDA receptors, as has been proposed for glutamate binding to the GluR2 AMPA receptor subunit.
Book ChapterDOI
Highly active anticancer curcumin analogues.
TL;DR: Both simple curcumin analogues and the protein conjugate evidence antiangiogenic activity in cell culture, which implies that the fVIIa-TF targeting process, like the dienone drugs, permits a double-pronged attack with the potential to destroy a tumor directly by apoptosis.
Journal ArticleDOI
Total synthesis of SR 121463 A, a highly potent and selective vasopressin v(2) receptor antagonist.
TL;DR: A novel and stereoselective synthesis that stems from the preparation of three key intermediates: the substituted benzenesulfonyl chloride 2, the N-protected oxindole 3, and protected dibromide 4 is presented.
Journal ArticleDOI
The development of a selective cyclin-dependent kinase inhibitor that shows antitumor activity.
Simak Ali,Dean A. Heathcote,Sebastian H. B. Kroll,Ashutosh S. Jogalekar,Bodo Scheiper,Hetal Patel,Jan Brackow,Alekasandra Siwicka,Matthew J. Fuchter,Manikandan Periyasamy,Robert S. Tolhurst,Seshu K. Kanneganti,James P. Snyder,Dennis C. Liotta,Eric O. Aboagye,Anthony G. M. Barrett,R. Charles Coombes +16 more
TL;DR: BS-181, a pyrazolo[1,5-a]pyrimidine-derived compound, provides the first example of a potent and selective CDK7 inhibitor with potential as an anticancer agent.